Page 128 - NobleCon20-Book-Project

Health Care
Date November 18, 2024 Health Care
52wk High $2.11
52wk Low $0.36 Ocugen, Inc. OCGN $0.91
11 Great Valley Parkway
Malvern, PA 19355

(USD - in millions) www.ocugen.com
Market Cap 273.4
Enterprise 241.5
Basic Shares Out. 291.32 COMPANY OVERVIEW
Float 287.37
Institutional Holdings 27.43% Detailed Analysis:Channelchek.com
Short Interest 50.65
Avg. 90-Day Volume 3.63 Ocugen, Inc. is a biotechnology company focused on discovering,
developing, and commercializing novel gene and cell therapies and
vaccines that improve health and offer hope for patients across the
globe. We are making an impact on patient’s lives through courageous
EPS Data innovation—forging new scientific paths that harness our unique
intellectual and human capital. Our breakthrough modifier gene therapy
2022 2023 2024 platform has the potential to treat multiple retinal diseases with a single
CQ1 (0.09) (0.07) (0.05) product, and we are advancing research in infectious diseases to
CQ2 (0.09) (0.10) (0.04) support public health and orthopedic diseases to address unmet
medical needs.
CQ3 (0.10) (0.06) (0.05)
CQ4 (0.10) (0.03) (0.06)
CY (0.38) (0.26) (0.20) Source: Channelchek/QuoteMedia

Long-Term EPS Estimate N/A
Price/Book (mrq) 0.14
ROE (ttm) -103.30
Debt-to-Total Cap. (mrq) 14.31
Fiscal Year End 31-Dec
11 Great Valle Malvern PA 19355

Key Executives
CEO: Musunuri, Shankar
CFO: N/A
COO: N/A
IR: N/A
Noble Capital Markets, Inc.
Source: Capital IQ, Noble Financial estimates, company filings
Noble Senior Analyst 561-994-1191 noblecapitalmarkets.com
Robert LeBoyer MEMBERS: FINRA, SIPC, MSRB
Following the conference, complete video library of presentations will be
rleboyer@noblelsp.com available at: channelchek.com | nobleconference.com
(212) 896-4625

Refer to the back of the book for disclosures